Measuring Sirtuin Activity in Cancer Cells
Official title: A Bioluminescent Assay for Direct Measurement of Sirtuin Activity in Cancer Cells
Funded at Versiti Wisconsin, INC. · NIH-10486045 · Data updated 2026-11-12
This study is working on a new way to see how certain proteins called sirtuins are working in cancer cells, which could help scientists better understand cancer and develop new treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | September 10, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $296,084 |
| NIH project number | 5R21CA256128-02 |
| Project ID | NIH-10486045 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from targeted therapies that modulate sirtuin activity.
✕Less likely to help
Patients with non-malignant conditions or those not diagnosed with cancer may not receive any benefit from this research.
What this research studies
This research focuses on developing a new bioluminescent assay to measure the activity of sirtuins, which are proteins that play a crucial role in regulating various cellular functions, including cancer development. The assay aims to provide real-time insights into sirtuin activity within cancer cells, overcoming limitations of existing methods that are often inaccurate or lack sensitivity. By using a novel luciferase-based approach, the researchers hope to create a reliable tool for studying sirtuins in both laboratory and animal models, which could aid in drug development and understanding cancer biology.
Why it matters
Potential benefit: If successful, this research could lead to improved methods for assessing cancer treatment effectiveness and developing new therapies targeting sirtuin activity.
How similar studies have gone: While the approach of using bioluminescent assays is established, the specific application to real-time measurement of sirtuin activity in cancer cells is relatively novel and has not been extensively tested.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Deininger, Michael W. — Versiti Wisconsin, INC.
- Study coordinator: Deininger, Michael W.
Related research
Other NIH-funded projects on the same topics.
-
Improving blood safety and availability for transfusions in children and adults
This study is looking to make blood transfusions safer and more accessible for both kids and adults by gathering information from blood donors and recipients across the US and Brazil, so that everyone can benefit from better transfusion practices in the future.
-
Understanding how to safely increase fetal hemoglobin for treating blood disorders
This study is looking at how to safely boost fetal hemoglobin levels in people with blood disorders like beta-thalassemia, by exploring new ways to change certain cells in the body, so that patients can have better treatment options.
-
Understanding how certain proteins regulate blood clotting and cardiovascular diseases
This study is looking at how two proteins that help with blood clotting and heart health work, which could lead to better treatments for blood clotting disorders and heart disease.
-
Targeting a specific gene to treat a type of leukemia
This study is testing a new treatment called AI-10-49 for people with acute myeloid leukemia who have a specific genetic change that makes their condition harder to treat, and it aims to help these patients live longer by killing leukemia cells and working better with other medications.
-
Understanding maternal immune responses affecting newborns with low platelet counts
This study is looking at how a mother's immune system can affect her baby's platelets, which might lead to a serious bleeding condition in newborns, and it aims to find out which pregnancies are at higher risk so that better tests and prevention methods can be developed to help keep babies safe.
-
Understanding the immune response in patients with heparin-induced thrombocytopenia
This study is looking at how the immune system responds to heparin, a blood thinner, to find out more about a serious condition called heparin-induced thrombocytopenia (HIT), and it aims to help doctors better identify harmful antibodies in patients, even if their regular tests come back normal, so they can prevent ser
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.